The neutrophil to lymphocyte ratio associates with markers of Alzheimer's disease pathology in cognitively unimpaired elderly people.

Autor: Jacobs T; New York University (NYU) Grossman School of Medicine., Jacobson SR; New York University (NYU) Grossman School of Medicine., Fortea J; Hospital de la Santa Creu y Sant Pau, Universitat Autònoma de Barcelona., Berger JS; NYU Grossman School of Medicine., Vedvyas A; New York University (NYU) Grossman School of Medicine., Marsh K; New York University (NYU) Grossman School of Medicine., He T; New York University (NYU) Grossman School of Medicine., Gutierrez-Jimenez E; Aarhus University., Fillmore NR; MAVERIC, Boston Healthcare System., Bubu OM; New York University (NYU) Grossman School of Medicine., Gonzalez M; New York University (NYU) Grossman School of Medicine., Figueredo L; New York University (NYU) Grossman School of Medicine., Gaggi NL; New York University (NYU) Grossman School of Medicine., Plaska CR; New York University (NYU) Grossman School of Medicine., Pomara N; New York University (NYU) Grossman School of Medicine., Blessing E; New York University (NYU) Grossman School of Medicine., Betensky R; New York University (NYU) Grossman School of Medicine., Rusinek H; New York University (NYU) Grossman School of Medicine., Zetterberg H; University of Gothenburg., Blennow K; University of Gothenburg., Glodzik L; Weill Cornell Medicine., Wisniewski TM; New York University (NYU) Grossman School of Medicine., Leon MJ; New York University (NYU) Grossman School of Medicine., Osorio RS; New York University (NYU) Grossman School of Medicine., Ramos-Cejudo J; NYU Grossman School of Medicine.
Jazyk: angličtina
Zdroj: Research square [Res Sq] 2024 Mar 14. Date of Electronic Publication: 2024 Mar 14.
DOI: 10.21203/rs.3.rs-4076789/v1
Abstrakt: Background: An elevated neutrophil-lymphocyte ratio (NLR) in blood has been associated with Alzheimer's disease (AD). However, an elevated NLR has also been implicated in many other conditions that are risk factors for AD, prompting investigation into whether the NLR is directly linked with AD pathology or a result of underlying comorbidities. Herein, we explored the relationship between the NLR and AD biomarkers in the cerebrospinal fluid (CSF) of cognitively unimpaired (CU) subjects. Adjusting for sociodemographics, APOE4, and common comorbidities, we investigated these associations in two cohorts: the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the M.J. de Leon CSF repository at NYU. Specifically, we examined associations between the NLR and cross-sectional measures of amyloid-β42 (Aβ42), total tau (t-tau), and phosphorylated tau 181 (p-tau), as well as the trajectories of these CSF measures obtained longitudinally.
Results: A total of 111 ADNI and 190 NYU participants classified as CU with available NLR, CSF, and covariate data were included. Compared to NYU, ADNI participants were older (73.79 vs. 61.53, p < 0.001), had a higher proportion of males (49.5% vs. 36.8%, p = 0.042), higher BMIs (27.94 vs. 25.79, p < 0.001), higher prevalence of hypertensive history (47.7% vs. 16.3%, p < 0.001), and a greater percentage of Aβ-positivity (34.2% vs. 20.0%, p = 0.009). In the ADNI cohort, we found cross-sectional associations between the NLR and CSF Aβ42 (β=-12.193, p = 0.021), but not t-tau or p-tau. In the NYU cohort, we found cross-sectional associations between the NLR and CSF t-tau (β = 26.812, p = 0.019) and p-tau (β = 3.441, p = 0.015), but not Aβ42. In the NYU cohort alone, subjects classified as Aβ+ (n = 38) displayed a stronger association between the NLR and t-tau (β = 100.476, p = 0.037) compared to Aβ- subjects or the non-stratified cohort. In both cohorts, the same associations observed in the cross-sectional analyses were observed after incorporating longitudinal CSF data.
Conclusions: We report associations between the NLR and Aβ42 in the older ADNI cohort, and between the NLR and t-tau and p-tau 181 in the younger NYU cohort. Associations persisted after adjusting for comorbidities, suggesting a direct link between the NLR and AD. However, changes in associations between the NLR and specific AD biomarkers may occur as part of immunosenescence.
Competing Interests: Competing Interests HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for AC Immune, Acumen, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The other authors declare no competing interests.
Databáze: MEDLINE
Externí odkaz: